A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease, Pulsus Group Inc
CANADIAN RESPIRATORY JOURNAL
The Canadian Thoracic Society (CTS) Canadian Respiratory Health Professionals Canadian Critical Care Society (CCCS)

Abstract

Note: (Optional)

Citation Builder

  •  
Return to Table of Contents
 
Original Articles November/December 2007, Volume 14 Issue 8: 465-472
 

A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease

CK Chan | F Maltais | C Sigouin | JM Haddon | GT Ford | on behalf of the SAFE Study Group

BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) who smoke have a greater annual rate of decline in forced expiratory volume in 1 s (FEV1) than those patients who have stopped smoking.
OBJECTIVES: To assess the effect of tiotropium on pre-dose (trough) FEV1 in patients with COPD followed in Canada.
METHODS: A total of 913 patients were randomly assigned to receive either tiotropium 18 µg once daily (n=608) or placebo (usual care minus inhaled anticholinergics) (n=305) for 48 weeks in the present randomized, double-blind, parallel-group study. The effect of tiotropium on measurements of lung function (FEV1, FEV6 and forced vital capacity), symptoms, health-related quality of life (St George's Respiratory Questionnaire) and exacerbations were examined.
RESULTS: Tiotropium improved trough FEV1 in both current and ex-smokers compared with placebo. Baseline FEV1 in smokers and ex-smokers was 1.03 L and 0.93 L, respectively (P<0.001). At week 48, the mean difference between the tiotropium and placebo groups was 0.14±0.04 L (P<0.001) in the smoker group and 0.08±0.02 L (P<0.0001) in the ex-smoker group. Tiotropium also significantly improved trough forced vital capacity and FEV6 compared with placebo throughout the treatment period (P<0.05, for all). Furthermore, tiotropium significantly improved the St George's Respiratory Questionnaire total score compared with placebo at week 48 (40.9 versus 43.7 units, P<0.005).
CONCLUSIONS: Compared with the placebo group, tiotropium provides sustained improvements in lung function in patients with COPD, with improvements for smokers and ex-smokers.

COPD | Placebo | Randomized | Smoking | Tiotropium
   Français   
          
Click to download PDF Reader
 
 




Copyright © Pulsus Group Inc.